Oppenheimer Issues Positive Forecast for Alumis (NASDAQ:ALMS) Stock Price

Alumis (NASDAQ:ALMS) had its price target increased by Oppenheimer from $50.00 to $55.00 in a research note issued to investors on Monday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts also recently commented on ALMS. Wells Fargo & Company boosted their target price on Alumis from $17.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Alumis in a report on Monday. Leerink Partners lifted their price objective on Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday, January 6th. Loop Capital set a $37.00 price objective on Alumis in a research note on Wednesday, January 21st. Finally, UBS Group restated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.60.

Alumis Stock Down 18.5%

Shares of Alumis stock opened at $20.21 on Monday. Alumis has a 12-month low of $2.76 and a 12-month high of $30.60. The stock has a market capitalization of $2.57 billion, a P/E ratio of -6.60 and a beta of -2.16. The company has a 50-day simple moving average of $26.50 and a 200 day simple moving average of $14.67.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The firm had revenue of $1.93 million during the quarter, compared to analyst estimates of $2.75 million. Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. On average, equities analysts anticipate that Alumis will post -8.51 earnings per share for the current year.

Insider Transactions at Alumis

In other news, major shareholder Foresite Capital Management Vi purchased 411,764 shares of the business’s stock in a transaction dated Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the purchase, the insider directly owned 5,702,536 shares of the company’s stock, valued at $96,943,112. The trade was a 7.78% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James B. Tananbaum acquired 411,764 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was purchased at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the transaction, the director owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 1,823,527 shares of company stock worth $30,999,959 in the last quarter. 40.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Alumis by 64.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after purchasing an additional 4,926 shares during the period. Goldman Sachs Group Inc. lifted its stake in Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after buying an additional 11,949 shares during the period. Jane Street Group LLC acquired a new position in Alumis in the first quarter valued at about $111,000. Rhumbline Advisers boosted its holdings in Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after buying an additional 2,949 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Alumis by 163.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock worth $3,504,000 after buying an additional 724,133 shares during the period.

Key Stories Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target to $55 and kept an “outperform” rating, signaling strong upside from current levels and giving investors a bullish institutional vote of confidence. Oppenheimer raises PT to $55 (Benzinga)
• Positive Sentiment: Morgan Stanley (coverage noted on TipRanks) maintained a Buy rating with a $38 target, citing strong Phase 3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a near‑term clinical/regulatory catalyst. Morgan Stanley maintains Buy (TipRanks)
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $38 target, reinforcing analyst conviction around the clinical story and longer‑term upside. Chardan reaffirms Buy (Benzinga)
• Neutral Sentiment: HC Wainwright trimmed its target from $40 to $25 but left a “buy” rating intact — a mixed signal (reduced upside but continued positive view). HC Wainwright lowers PT to $25 (Benzinga)
• Negative Sentiment: Intraday selling is being attributed to investors locking in gains after roughly a 239% annual rise; technical commentary notes the stock tested/broke short‑term support levels, amplifying the drop. Why Is Alumis Stock Falling Monday? (Benzinga)
• Negative Sentiment: Fundamental pressures remain — recent quarter missed revenue and EPS expectations and the company shows deeply negative margins and ROE — which can make pullbacks sharper and raise the bar for sustained rallies. (Background: Q1 results and metrics)

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.